| Symbol | INAB |
|---|---|
| Name | IN8BIO, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 350 5TH AVENUE,SUITE 5330, NEW YORK, New York, 10118, United States |
| Telephone | +1 646 600-6438 |
| Fax | — |
| — | |
| Website | https://www.in8bio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001740279 |
| Description | IN8bio Inc is a clinical-stage biotechnology company. It is focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - IN8BIO, INC. <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0000935836-26-000398 <b>Size:</b> 12 KB
Read moreIN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Read moreIN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies
Read moreIN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026
Read moreNew Form 424B5 - IN8BIO, INC. <b>Filed:</b> 2026-06-01 <b>AccNo:</b> 0001193125-26-249564 <b>Size:</b> 2 MB
Read moreFAIRBAIRN EMILY 🔴 sold 724.6K shares of IN8BIO, INC. (INAB) Transaction Date: May 27, 2026 | Filing ID: 000006
Read moreNew Form SCHEDULE 13D/A - IN8BIO, INC. <b>Filed:</b> 2026-05-29 <b>AccNo:</b> 0001682638-26-000008 <b>Size:</b> 11 KB
Read moreNew Form S-3/A - IN8BIO, INC. <b>Filed:</b> 2026-05-18 <b>AccNo:</b> 0001193125-26-229132 <b>Size:</b> 378 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05664243 | A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allog… | Phase1 | Glioblastoma | Active_Not_Recruiting | 2023-09-08 | 2025-12-01 | ClinicalTrials.gov |
| NCT03533816 | Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cel… | Phase1 | Acute Myeloid Leukemia | Recruiting | 2020-01-31 | 2028-01-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Allogeneic genetically modified gamma-delta T cells | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT05664243 |
| Autologous genetically modified gamma-delta T cells | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT05664243 |
| EAGD T-cell infusion (Expansion) | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT03533816 |
| EAGD T-cell infusion (Phase I) | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT03533816 |
| Allogeneic genetically modified gamma-delta T cells | BIOLOGICAL | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT05664243 |
| Autologous genetically modified gamma-delta T cells | BIOLOGICAL | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT05664243 |
| EAGD T-cell infusion (Expansion) | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT03533816 |
| EAGD T-cell infusion (Phase I) | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT03533816 |